文献速递乳腺MR

雌激素受体阳性、HER2阴性、淋巴结阴性乳腺癌的弥散加权MRI:瘤内异质性与复发风险的关系

Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
PubMed 文献 · Eur Radiol · 2019-08-05

本研究回顾性纳入105例接受Oncotype DX检测及术前DWI的ER阳性、HER2阴性、淋巴结阴性乳腺癌女性,采用全病灶ADC直方图分析评估瘤内异质性。低复发风险组(RS<18)的ADC差值低于非低复发风险组(0.600×10⁻³ mm²/s vs 0.746×10⁻³ mm²/s,p<0.001)。校正临床病理因素后,较低的ADC差值(<0.559×10⁻³ mm²/s;OR=5.998;p=0.007)和较小肿瘤(≤2 cm;OR=3.866;p=0.012)与低复发风险相关。

要点

  • 全病灶ADC直方图分析的ADC差值可量化瘤内异质性,低风险组低于非低风险组。
  • ADC差值<0.559×10⁻³ mm²/s及肿瘤≤2 cm与低复发风险独立相关。
  • ADC差值可能作为ER阳性、HER2阴性、淋巴结阴性乳腺癌复发风险的定量DWI标志物。

核心结论

  • 全病灶ADC直方图分析得出的ADC差值可能作为ER阳性、HER2阴性、淋巴结阴性浸润性乳腺癌复发风险的定量DWI生物标志物。

研究设计与样本

  • 回顾性研究,纳入105例(中位年龄48岁)接受Oncotype DX检测及术前DWI的ER阳性、HER2阴性、淋巴结阴性乳腺癌女性;对全肿瘤像素ADC数据进行直方图分析,提取均值及第5、25、50、75、95百分位ADC值,并以第5与第95百分位ADC之差定义ADC差值。

关键影像表现/征象

  • 全病灶直方图分析显示,低复发风险组(RS<18)的ADC差值为0.600×10⁻³ mm²/s,非低复发风险组(RS≥18,中至高风险)为0.746×10⁻³ mm²/s,两组差异有统计学意义(p<0.001)。

诊断标准与关键数值

  • 以Oncotype DX复发评分(RS)分层:低复发风险为RS<18,非低复发风险为RS≥18(中至高风险)。
  • ADC差值定义为第5与第95百分位ADC值之差,用于评估瘤内异质性。
  • 多因素回归分析显示,较低的ADC差值(<0.559×10⁻³ mm²/s;OR=5.998;p=0.007)与低复发风险相关。
  • 肿瘤较小(≤2 cm;OR=3.866;p=0.012)与低复发风险相关。

临床应用与阅片要点

  • 在ER阳性、HER2阴性、淋巴结阴性乳腺癌的术前DWI评估中,可尝试全病灶ADC直方图分析并计算ADC差值以辅助评估复发风险。
  • ADC差值较低(<0.559×10⁻³ mm²/s)及肿瘤≤2 cm可能提示低复发风险,可结合Oncotype DX复发评分综合判断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay.

METHODS: This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated.

RESULTS: Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS ≥ 18; intermediate to high risk of recurrence) groups (0.600 × 10-3 mm2/s vs. 0.746 × 10-3 mm2/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 × 10-3 mm2/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (≤ 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors.

CONCLUSIONS: The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.

KEY POINTS: • A lower ADC difference value and a small tumor size were associated with a low risk of recurrence of breast cancer. • The ADC difference value could be a quantitative marker for intratumoral heterogeneity. • Whole-lesion histogram analysis of the ADC could be helpful for discriminating the low-risk from non-low-risk recurrence groups.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim JY, Kim JJ, Hwangbo L, et al. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk. Eur Radiol. 2019. PMID: 31385051. doi:10.1007/s00330-019-06383-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。